# Aleix Prat

Source: https://onco.cc/people/aleix-prat/  
OnCo record `aleix-prat` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Translational oncologist who built genomic tests (HER2DX) to decide which HER2-positive patients can skip chemotherapy.

## Summary

Aleix Prat developed the HER2DX genomic assay and led PAM50-based analyses across breast cancer trials, and is a principal investigator of PHERGain, which uses PET response to omit chemotherapy in HER2-positive early disease. He directs medical oncology at Hospital Clínic and the SOLTI cooperative group, focusing on biology-guided de-escalation.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: breast; genomics; de-escalation
- Role: Head of Medical Oncology, Hospital Clínic de Barcelona; Scientific Director, SOLTI
- Specialisms: Breast cancer genomics; HER2-positive de-escalation; PAM50 and HER2DX; Neoadjuvant trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Prat%20A%5BAuthor%5D%20breast%20PAM50%20HER2DX

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- technologies: [FDG PET](https://onco.cc/technologies/fdg-pet/), [RNA sequencing & expression profiling](https://onco.cc/technologies/rna-seq/)
- companies: [SOLTI Cancer Research Group](https://onco.cc/companies/solti/)
- institutions: [Hospital Clínic de Barcelona / IDIBAPS](https://onco.cc/institutions/hospital-clinic-barcelona/)
- trials: [PHERGain](https://onco.cc/trials/phergain/)
- journals: [The Breast](https://onco.cc/journals/the-breast/)
- key papers: [Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer](https://onco.cc/key-papers/paper-schettini-her2-low-features-npj-breast-cancer-2021/)

---
JSON: https://onco.cc/api/v1/entities/aleix-prat.json